Children and adolescents in low- and middle-income countries living with HIV showed a reduced viral load after treatment with ...

Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.

HIV-1 protease is a critical enzyme in the viral life cycle, facilitating the maturation of infectious viral particles by cleaving precursor polyproteins. The emergence of drug resistance, driven by ...

Weight gain associated with integrase strand transfer inhibitor-based antiretroviral therapy (ART) may be mitigated or reversed over time by switching to protease inhibitor-based ART. For patients ...

More than 40 years of AIDS research has led to significant advancements in treatment and prevention. Drugs to treat the infection continued to improve, as did patient outcomes. But now there's another ...

NEW YORK (Reuters) - Johnson & Johnson said on Tuesday its drug Prezista was as effective in a late-stage trial as Abbott Laboratories Inc's Kaletra in cutting HIV to undetectable levels among ...

As of today, the central role of mitochondrial metabolism associated with tumorigenesis and progression of malignancies has been deeply investigated. Moreover, oxidative phosphorylation inhibition ...

The US Food and Drug Administration (FDA) has approved 2 new HIV-1 cocktail drugs from Gilead Sciences, one an integrase inhibitor called elvitegravir (Vitekta) and the other a protease-inhibitor ...

New York, NY, and Tel Aviv, ISRAEL, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today ...

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

"Time has stood still" for many who've been on complex regimens for decades ...